Effect of neurokinin-1 receptor antagonists on the function of 5-HT and noradrenaline neurons

NeuroReport

Volumn 11, Issue 6, 2000, Pages 1323-1327

  Haddjeri, Nasser ^a   Blier, Pierre ^a  

^a MCGILL UNIVERSITY   (Canada)

Author keywords

8 OH DPAT; Anxiety; Clonidine; CP 96,345; Depression; Dorsal raphe; Locus coeruleus; LSD; NK1 receptor; WIN 51,708

Indexed keywords

17ALPHA ETHYNYL 17BETA HYDROXY 5ALPHA ANDROSTANO[3,2 B]PYRIMIDO[1,2 A]BENZIMIDAZOLE; 2 BENZHYDRYL 3 (2 METHOXYBENZYLAMINO) 1 AZABICYCLO[2.2.2]OCTANE; 2 BROMO N (2 CHLOROETHYL) N ETHYLBENZYLAMINE; N [2 [4 (2 METHOXYPHENYL) 1 PIPERAZINYL]ETHYL] N (2 PYRIDYL)CYCLOHEXANECARBOXAMIDE; NEUROKININ 1 RECEPTOR ANTAGONIST; NORADRENALIN; SEROTONIN; 2 DIPROPYLAMINO 8 HYDROXYTETRALIN; ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; ALPHA ADRENERGIC RECEPTOR STIMULATING AGENT; ANDROSTANE DERIVATIVE; BENZIMIDAZOLE DERIVATIVE; BENZYLAMINE DERIVATIVE; BIPHENYL DERIVATIVE; CLONIDINE; LYSERGIDE; NEUROKININ 1 RECEPTOR; PIPERAZINE DERIVATIVE; PYRIDINE DERIVATIVE; SEROTONIN AGONIST; SEROTONIN ANTAGONIST;

ANIMAL CELL; ANXIETY; ARTICLE; DEPRESSION; DORSAL RAPHE NUCLEUS; DRUG EFFECT; ELECTROPHYSIOLOGY; FOREBRAIN; LOCUS CERULEUS; NEUROTRANSMITTER RELEASE; NONHUMAN; PRIORITY JOURNAL; RAT; SLEEP WAKING CYCLE; STIMULUS RESPONSE; SYNAPTIC TRANSMISSION; ANIMAL; CYTOLOGY; DOSE RESPONSE; DRUG ANTAGONISM; INTRAPERITONEAL DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; MALE; METABOLISM; NERVE CELL; RAPHE NUCLEUS; SPRAGUE DAWLEY RAT;

8-HYDROXY-2-(DI-N-PROPYLAMINO)TETRALIN; ADRENERGIC ALPHA-AGONISTS; ADRENERGIC ALPHA-ANTAGONISTS; ANDROSTANES; ANIMALS; BENZIMIDAZOLES; BENZYLAMINES; BIPHENYL COMPOUNDS; CLONIDINE; DOSE-RESPONSE RELATIONSHIP, DRUG; INJECTIONS, INTRAPERITONEAL; INJECTIONS, INTRAVENOUS; LOCUS COERULEUS; LYSERGIC ACID DIETHYLAMIDE; MALE; NEURONS; NOREPINEPHRINE; PIPERAZINES; PYRIDINES; RAPHE NUCLEI; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, NEUROKININ-1; SEROTONIN; SEROTONIN AGONISTS; SEROTONIN ANTAGONISTS;

EID: 0034719969     PISSN: 09594965     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001756-200004270-00035     Document Type: Article

References (32)

1. 1. Blier P and de Montigny C. Trends Pharmacol Sci 15, 220-225 (1994).
2. 2. Delgado P and Moreno F. Int Clin Psychopharmacol 14, S9-S16 (1999).
3. 3. Rosen A, Brodln K, Eneroth P and Brodin E. Acta Physiol Scand 146, 341-348 (1992).
4. 4. Shirayama Y, Mitsushio H, Takashima M et al. Brain Res 739, 70-78 (1996).
5. 5. Brodin E, Rosen A Schott E and Brodin K. Neuropeptides 26, 253-260 (1994).
6. 6. Saria A. Eur J Pharmacol 375, 51-60 (1999).
7. 7. Kramer MS, Cutler N, Feighner J et al. Science 281, 1640-1645 (1998).
8. 8. Sergeyev V, Hökfelt T and Hurd Y. Neuroreport 10, 3967-3970 (1999).
9. 9. Guyenet PG and Aghajaruan GK. Brain Res 136, 178-184 (1977).
10. 10. Quirion R, Shults CW, Moody TW et al. Nature 303, 714-716 (1983).
11. 11. McLean S, Ganong AH, Seeger T et al. Science 251, 437-439 (1991).
12. 12. Pham TM and Couture R. Naunyn-Schmiedebergs Arch Pharmacol 347, 34-41 (1993).
13. 13. Anderson JJ, Kuo S, Chase TN and Engberg TM. J Pharmacol Exp Ther 269, 1144-1151 (1994).
14. 14. Mongeau R, Blier P and de Montigny C. Brain Res Rev 23, 145-195 (1997).
15. 15. Piñeyro G and Blier P. Pharmacol Rev 51, 533-591 (1999).
16. 16. Magoul R, Onteniente B, Oblin A and Calas A. J Histochem Cytochem 34, 735-742 (1986).
17. 17. Dean C, Marson L and Kampine JP. Neuroscience 57, 811-822 (1993).
18. 18. Gradin K, Qadri F, Nomikos GG et al. Eur J Pharmacol 218, 363-367 (1992).
19. 19. Ono H, Mishima A, Ono S et al. Neuropharmacology 30, 585-589 (1991).
20. 20. Nance PW and Sawynok J. J Pharmacol Exp Ther 240, 972-977 (1987).
21. 21. Jones RS and Olpe HR. Brain Res 311, 297-305 (1984).
22. 22. Shen KZ and North RA. Neuroscience 50, 345-353 (1992).
23. 23. Arima J, Kubo CV, Ishibashi H and Akaike N. J Physiol (Lond) 508, 57-66 (1998).
24. 24. Kaehler ST, Singewald N and Philippu A. Naunyn-Schmiedebergs Arch Pharmacol 359, 386-393 (1999).
25. 25. Wang H, Li KY, Wu GC and Cao XD. Acupunct Electrother Res 20, 163-172 (1995).
26. 26. Hamamura T, Lee Y, Fujiwara Y and Kuroda S. Brain Res 759, 156-159 (1997).
27. 27. Hahn MK and Bannon MJ. Eur J Pharmacol 348, 155-160 (1998).
28. 28. Haigler HJ and Spring DD. Eur J Pharmacol 67, 65-74 (1980).
29. 29. Tsou MY, Len WB, Lee TY et al Brain Res 653, 183-190 (1994).
30. 30. Velimirovic BM, Koyano K, Nakajima S and Nakajima Y. Proc Natl Acad Sci USA 92, 1590-1594 (1995).
31. 31. Ruiz-Ortega JA and Ugedo L. Naunyn-Schmiedebergs Arch Pharmacol 355, 288-294 (1997).
32. 32. Haddjeri N, Blier P and de Montigny C. J Neurosci 19, 10150-10156 (1998).